NCT00998283View on ClinicalTrials.gov

Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Healthy
Interventions
DRUG

HM10460A 5μg/kg

Subcutaneously administrate at 0 hour on Day 1

DRUG

HM10460A 15μg/kg

Subcutaneously administrate at 0 hour on Day 1

DRUG

HM10460A 45μg/kg

Subcutaneously administrate at 0 hour on Day 1

DRUG

HM10460A 135μg/kg

Subcutaneously administrate at 0 hour on Day 1

DRUG

HM10460A 350μg/kg

Subcutaneously administrate at 0 hour on Day 1

DRUG

Placebo

Subcutaneously administrate at 0 hour on Day 1

Trial Locations (1)

Unknown

Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT00998283 - Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects | Biotech Hunter | Biotech Hunter